PT-141 / Tadalafil / Oxytocin

Rapid Dissolve Mini-Tabs

2 mg / 10 mg / 100 IU

Ready to prescribe?
Disclaimer: Images are for reference only; actual products may vary.

Product Overview

PT-1411,2

Bremelanotide (PT-141) is a melanocortin receptor (MCR) agonist. It is indicated for the treatment of premenopausal women with acquired, generalized hypoactive sexual desire disorder (HSDD), defined as low sexual desire causing significant distress or interpersonal difficulty and not attributable to:

  • A coexisting medical or psychiatric condition
  • Relationship-related issues or the effects of medications or other substances

Tadalafil Description3,4

Tadalafil is a phosphodiesterase type 5 (PDE5) inhibitor with a mean terminal half-life exceeding 17 hours, which is longer than that of other PDE5 inhibitors. This extended half-life supports once-daily or on-demand dosing. Tadalafil is indicated for the treatment of pulmonary arterial hypertension (PAH), erectile dysfunction (ED), benign prostatic hypertrophy (BPH), or the combined management of ED and BPH.

Oxytocin Description6-11

Oxytocin is a hormone produced in the hypothalamus and stored in the posterior pituitary gland. Synthetic oxytocin has identical activity to the naturally occurring hormone. Oxytocin stimulates smooth muscle contraction in the uterus during labor and triggers milk ejection from the alveolar ducts after milk production in the breast. Due to its uterine effects, it has been used to induce labor, assist in placenta delivery, and control postpartum bleeding. Oxytocin is also associated with social bonding, mood regulation, and sexual function.

PT-1411,2

Bremelanotide (PT-141), a MCR agonist, non-selectively works on several receptor subtypes MC1R-MC5R in the central nervous system. MC1R and MC4R are thought to be the most relevant. MC4R are commonly present in the central nervous system. Although the mechanism of action is not fully elucidated, the drug is thought to activate pathways in the brain that are involved in sexual responses.

Tadalafil3-5

Phosphodiesterase (PDE) has many isoforms and is an enzyme that has many functions in the body including degrading the effect of cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP). PDE5 is an enzyme that is found in many parts of the body including in the smooth muscle of the corpus cavernosum, prostate, bladder, the vascular and visceral smooth muscle, skeletal muscle, urethra, platelets, kidney, lung, cerebellum, heart, liver, testis, seminal vesicle, and pancreas. Tadalafil is a selective inhibitor of PDE5, the enzyme responsible for the degradation of cGMP. The drug has selective activity on PDE5 than other phosphodiesterase isoforms. Tadalafil activity on PDE5 is more than 10,000-fold more than for PDE1, PDE2, PDE4, and PDE7 enzymes. Increased cGMP leads to smooth muscle relaxation in the corpus cavernosum which can help in maintaining an erection.

Oxytocin6-11

Oxytocin causes G-protein coupled receptors to increase intracellular calcium which leads to uterine contraction. The stimulation of uterine contractions causes more oxytocin to be released. As more oxytocin is released it positively influences even more release of oxytocin. This release of oxytocin is called positive feedback which is much different than how many hormones work in the endocrine system. Oxytocin administered exogenously causes the same response as endogenously produced oxytocin. Not only does oxytocin stimulate uterine contractions, but it also causes contractions of myoepithelial cells in the alveolar ducts found in female breast tissue. These contractions force milk from these ducts into even larger sinuses, which subsequently enables milk expulsion. When a baby attempts to latch onto the mother’s breast it causes oxytocin secretion into the blood in the same manner as vaginal delivery; instead of uterine contractions, milk is ejected from the breast. Similar to the actions of oxytocin in the uterus to stimulate contractions during delivery, milk-ejection from breast tissue occurs due to positive feedback. In the brain, it is proposed that oxytocin stimulates social and sexual function by its activity in many areas of the brain including its activity on neurotransmitters.

PT-1411,2

Common

  • Gastrointestinal including nausea and vomiting
  • Increased blood pressure
  • Hyperpigmentation

 

Tadalafil3-5

Common 

  • Headache
  • Dyspepsia
  • Flushing
  • Back pain and myalgia (typically delayed onset, resolving within 48 hours)
  • Nasal congestion
  • Pain in limbs

 

Oxytocin6-11

Common

  • Loss of appetite
  • Nausea, vomiting
  • Stomach pain.

PT-1411,2

Contraindications:

  • Known hypersensitivity to bremelanotide or any component of the formulation
  • Patients with uncontrolled hypertension and cardiovascular disease
  • Pregnancy not recommended when taking bremelanotide

Precautions:

  • Use caution in patients with renal or hepatic impairment

 

Tadalafil3-5

Contraindications

  • Known hypersensitivity to tadalafil or tablet excipients
  • Use of nitrates and guanylate cyclase (GC) stimulators therapy, such as riociguat due to risk of life-threatening hypotension

Precautions

  • Use with caution in patients with:
  • Severe hepatic impairment (Child-Pugh Class C)
  • Severe renal impairment (creatinine clearance <30 mL/min)
  • Retinitis pigmentosa (rare inherited retinal disorder)
  • History of NAION (non-arteritic anterior ischemic optic neuropathy)
  • Recent history of myocardial infarction, stroke, or unstable angina

 

Oxytocin6-11

Contraindications

  • Known hypersensitivity to oxytocin
  • Pregnancy 1st or 2nd trimester

Precautions

  • Oxytocin may possess antidiuretic effects—extended administration may increase risk of fluid overload
  • Cardiovascular disease, due to oxytocin’s potential vasopressor effects
  • Store at controlled room temperature (20°C to 25°C / 68°F to 77°F)
  • Protect from moisture and light
  • Keep in a tightly closed container
  1. Bremelanotide package insert. www.accessdata.fda.gov/drugsatfda_docs/label/2019/210557s000lbl.pdf 
  2. Clinical Pharmacology bremelanotide clinical monograph 2025 https://www.clinicalkey.com/pharmacology/
  3.  Tadalafil Prescribing Information – Eli Lilly. www.accessdata.fda.gov/drugsatfda_docs/label/2011/021368s20s21lbl.pdf Revised October 2011. Accessed May 31, 2025
  4. Clinical Pharmacology Tadalafil clinical monograph 2025 https://www.clinicalkey.com/pharmacology/
  5. Padda IS, Tripp J. Phosphodiesterase Inhibitors. [Updated 2023 Jun 26]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK559276/
  6. Oxytocin Prescribing Information – Fresenius Kabi. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/018248s049lbl.pdf Revised September 2022. Accessed May 31, 2025
  7. Clinical Pharmacology Oxytocin clinical monograph 2025 https://www.clinicalkey.com/pharmacology/
  8. Osilla EV, Patel P, Sharma S. Oxytocin. [Updated 2025 Feb 15]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK507848/
  9. Kou J, Lan C, Zhang Y, Wang Q, Zhou F, Zhao Z, Montag C, Yao S, Becker B, Kendrick KM. In the nose or on the tongue? Contrasting motivational effects of oral and intranasal oxytocin on arousal and reward during social processing. Transl Psychiatry. 2021 Feb 4;11(1):94.
  10. Zhuang Q, Zheng X, Yao S, Zhao W, Becker B, Xu X, Kendrick KM. Oral Administration of Oxytocin, Like Intranasal Administration, Decreases Top-Down Social Attention. Int J Neuropsychopharmacol. 2022 Nov 17;25(11):912-923.
  11. Quintana DS, Glaser BD, Kang H, Kildal ESM, Audunsdottir K, Sartorius AM, Barth C. The interplay of oxytocin and sex hormones. Neurosci Biobehav Rev. 2024 Aug;163:105765.

WPPL operates as a 503A compounding pharmacy and prepares individualized prescription medications pursuant to provider direction. Compounded preparations are not reviewed, tested, or approved by the FDA.

This listing also includes commercially manufactured products for convenience; these items are not compounded by our pharmacy and are sold as provided by their manufacturers. Actual products in stock at time of dispensing may vary due to supply chain variability. Any statements regarding non-compounded products are manufacturer-supplied, have not been evaluated by the FDA, and are not intended to diagnose, treat, cure, or prevent any disease. WPPL does not verify or endorse any therapeutic claims made by manufacturers. Please refer to original labeling for complete product information.

EXPLORE MORE

Related Medications

Licensed to ship across the U.S.

Your orders arrive promptly and privately, delivered directly to your door.

Providers: Let’s Partner for Better Patient Care

If you are a physician, clinic, or practice seeking a dependable Compounding Pharmacy partner, WP Pharma Labs is here to help. With dedicated account setup, streamlined ordering and responsive service, we support your therapeutic goals with specialized compounds designed for your patients.

To check product availability, check on the status of an existing order, request refills:
orders@wppharmalabs.com

New providers setup / update an existing account:
newaccounts@wppharmalabs.com